137 related articles for article (PubMed ID: 17716630)
1. CRF1 not glucocorticoid receptors mediate prepulse inhibition deficits in mice overexpressing CRF.
Groenink L; Dirks A; Verdouw PM; de Graaff M; Peeters BW; Millan MJ; Olivier B
Biol Psychiatry; 2008 Feb; 63(4):360-8. PubMed ID: 17716630
[TBL] [Abstract][Full Text] [Related]
2. CRF
Verdouw PM; van Esterik JC; Peeters BW; Millan MJ; Groenink L
Pharmacol Biochem Behav; 2017 Mar; 154():11-19. PubMed ID: 28089628
[TBL] [Abstract][Full Text] [Related]
3. CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.
Douma TN; Millan MJ; Boulay D; Griebel G; Verdouw PM; Westphal KG; Olivier B; Groenink L
Psychopharmacology (Berl); 2014 Apr; 231(7):1289-303. PubMed ID: 24186076
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line.
Peeters BW; Ruigt GS; Craighead M; Kitchener P
Ann N Y Acad Sci; 2008 Dec; 1148():536-41. PubMed ID: 19120154
[TBL] [Abstract][Full Text] [Related]
5. Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating.
Flandreau E; Risbrough V; Lu A; Ableitner M; Geyer MA; Holsboer F; Deussing JM
Psychoneuroendocrinology; 2015 Mar; 53():16-28. PubMed ID: 25575243
[TBL] [Abstract][Full Text] [Related]
6. Valproate improves prepulse inhibition deficits induced by corticotropin-releasing factor independent of GABA(A) and GABA(B) receptor activation.
Douma TN; Millan MJ; Verdouw PM; Oosting RS; Olivier B; Groenink L
Neuropharmacology; 2014 Apr; 79():66-74. PubMed ID: 24211652
[TBL] [Abstract][Full Text] [Related]
7. Effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in two rat strains.
Conti LH; Murry JD; Ruiz MA; Printz MP
Psychopharmacology (Berl); 2002 May; 161(3):296-303. PubMed ID: 12021833
[TBL] [Abstract][Full Text] [Related]
8. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs.
Dirks A; Groenink L; Westphal KG; Olivier JD; Verdouw PM; van der Gugten J; Geyer MA; Olivier B
Neuropsychopharmacology; 2003 Oct; 28(10):1790-8. PubMed ID: 12865891
[TBL] [Abstract][Full Text] [Related]
9. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
Gannon RL; Millan MJ
Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice.
Peeters PJ; Fierens FL; van den Wyngaert I; Goehlmann HW; Swagemakers SM; Kass SU; Langlois X; Pullan S; Stenzel-Poore MP; Steckler T
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):135-50. PubMed ID: 15469890
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in Brown Norway and Wistar-Kyoto rats.
Conti LH
Eur J Pharmacol; 2005 Jan; 507(1-3):125-34. PubMed ID: 15659302
[TBL] [Abstract][Full Text] [Related]
12. New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
Nemeroff CB
Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-6. PubMed ID: 12404664
[TBL] [Abstract][Full Text] [Related]
13. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior.
Risbrough VB; Hauger RL; Roberts AL; Vale WW; Geyer MA
J Neurosci; 2004 Jul; 24(29):6545-52. PubMed ID: 15269266
[TBL] [Abstract][Full Text] [Related]
14. Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain.
Korosi A; Veening JG; Kozicz T; Henckens M; Dederen J; Groenink L; van der Gugten J; Olivier B; Roubos EW
Brain Res; 2006 Feb; 1072(1):46-54. PubMed ID: 16423327
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid receptor and treatment of psychotic major depression.
Hui X; Zhou CH; Wang MW
Yao Xue Xue Bao; 2005 Nov; 40(11):961-6. PubMed ID: 16499076
[No Abstract] [Full Text] [Related]
16. Critical time-window for the actions of adrenal glucocorticoids in behavioural sensitisation to cocaine.
de Jong IE; de Kloet ER
Eur J Pharmacol; 2009 Feb; 604(1-3):66-73. PubMed ID: 19121305
[TBL] [Abstract][Full Text] [Related]
17. The hypothalamopituitary-adrenal axis and alcohol preference.
O'Callaghan MJ; Croft AP; Jacquot C; Little HJ
Brain Res Bull; 2005 Dec; 68(3):171-8. PubMed ID: 16325017
[TBL] [Abstract][Full Text] [Related]
18. Reduced prepulse inhibition of startle in STAT6-deficient mice.
Yukawa K; Tanaka T; Owada-Makabe K; Tsubota Y; Bai T; Maeda M; Takeda K; Akira S; Iso H
Int J Mol Med; 2005 Oct; 16(4):673-5. PubMed ID: 16142403
[TBL] [Abstract][Full Text] [Related]
19. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive stress-free application of glucocorticoid ligands in mice.
Dalm S; Brinks V; van der Mark MH; de Kloet ER; Oitzl MS
J Neurosci Methods; 2008 May; 170(1):77-84. PubMed ID: 18308401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
